Ownership history in Voss Capital, LP Β· 5 quarters on record
This page tracks every 13F SEC filing in which Voss Capital, LP reported a position in ACTUATE THERAPEUTICS INC (ACTU). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π Voss Capital, LP underperformed the S&P 500 by β41.0% annually on this ACTU position. Timing score: 33% (1/3 decisions correct). Average cost basis: $6.24. Maximum drawdown during holding period: β23.2%.
β Significantly underperformed the S&P 500 by 41.0% ann.
4 quarters analyzed
β οΈ Poor timing β buys often preceded drops, trims preceded rallies.
1 of 3 add/trim decisions correct
Best entry: $6.11 (2025 Q2) Β· Worst: $7.96 (2024 Q4)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
4 adds Β· 0 trims. Bought during 3 of 3 down-price quarters. π Consistently bullish β fund kept accumulating this position.
π Voss Capital, LP has been actively increasing its ACTU allocation β a bullish signal from insiders.
Currently 0.38% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size